Oppenheimer & Co Analyst, Hartaj Singh, recently upgraded Moderna (MRNA) shares to "Outperform," with a price target of $142 per share. News of the upgrade has caused shares of the stock to trade over 13% higher on Tuesday. Hartaj Singh joins the Live show